Boye K1, García-Pérez LE2, Sapin H3, Rosilio M4, Orsini Federici M5, Heitmann E6, Jung H6, Gentilella R7, Aigner U8, Guerci B9, Giorgino F10, Norrbacka K11
1Eli Lilly and Company, Greenwood, IN, USA, 2Lilly, S.A., Alcobendas, Spain, 3Lilly France SAS, Neuilly Sur Seine , France, 4Lilly France SAS, Neuilly Sur Seine, France, 5Eli Lilly Company Italia SpA, Florence, Italy, 6Lilly Deutschland GmbH, Bad Homburg, Germany, 7Former employee of Eli Lilly Company Italia SpA, Florence, Italy, 8Versdias GmbH, Sulzbach-Rosenberg, Germany, 9Hôpital Brabois Adultes, CHRU de Nancy, France, 10University of Bari Aldo Moro, Bari, Italy, 11Eli Lilly and Company, Helsinki, Finland
OBJECTIVES: Patient-reported outcome (PRO) measures provide information that complement clinical data. However, studies assessing PROs of patients with type 2 diabetes (T2D) who initiate injectable glucose-lowering medications in routine clinical practice are limited. Here, we describe the perspectives of patients based on validated PRO measures at the time of enrollment (baseline) in the TROPHIES study. METHODS: TROPHIES is a 24-month, prospective, observational study in adult patients with T2D in France, Germany, and Italy, who initiate their first injectable glucose-lowering medication with once-weekly dulaglutide or once-daily liraglutide. To better understand the perspectives of patients regarding their overall health, treatment satisfaction, and quality of life and work, patients’ responses to the following questionnaires were collected at baseline before they initiated treatment with dulaglutide or liraglutide: EQ-5D-5L (scale: 0–1), EQ-VAS (scale: 0–100), Impact of Weight on Self‑Perceptions Questionnaire (IWSP; scale: 0–100), Diabetes Treatment Satisfaction Questionnaire-status (DTSQs; scale: 0–36), and Diabetes Productivity Measure (DPM; scale: 0–100). Higher scores reflect better outcomes. Analyses were descriptive in nature. RESULTS: To date, we have analyzed data from 2065 (dulaglutide: 1089; liraglutide: 976) patients. At baseline, patients initiating dulaglutide or liraglutide rated the quality of their lives in terms of mean EQ-5D-5L index as 0.84 and 0.83 and in terms of mean EQ-VAS as 67.5 and 67.7, respectively. The mean baseline scores in patients initiating dulaglutide or liraglutide were 59.9 and 61.3 for IWSP, 24.8 and 25.9 for DTSQs, 78.6 and 80.0 for DPM‑life productivity, and 87.4 and 86.8 DPM‑work productivity, respectively. CONCLUSIONS: The collection of PROs in clinical practice in patients with T2D complements clinical assessments when initiating the first GLP-1 RA treatment.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark